This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Bristol-Myers Squibb's $9-billion patent shielded as Indian court blocks biosimilar threat

By Freny Patel ( July 24, 2025, 00:11 GMT | Insight) -- Bristol-Myers Squibb secured an interim injunction to block Zydus Lifesciences' launch of its nivolumab biosimilar in India. The decision by the Delhi High Court protects BMS's $9 billion blockbuster cancer drug amid a patent dispute. The Indian court's ruling sends a clear message: while the "Bolar Exemption" permits clinical trials for biosimilars, any pre-launch commercial activities — such as manufacturing or stocking — before a patent's expiry are strictly forbidden. The next hearing is on Aug. 8.In a high-stakes legal battle, Bristol-Myers Squibb, or BMS, successfully obtained an interim injunction from an Indian court, protecting its $9 billion blockbuster cancer drug from Zydus Lifesciences' planned biosimilar launch....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login